Buscar
HOOKIPA Pharma Inc
HOOKAñadir a la lista de seguimiento
0.840USD
0.0000.00%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
10.14MCap. mercado
PérdidaP/E TTM
Más Datos de HOOKIPA Pharma Inc Compañía
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
Información de HOOKIPA Pharma Inc
Símbolo de cotizaciónHOOK
Nombre de la empresaHOOKIPA Pharma Inc
Fecha de salida a bolsaApr 18, 2019
Director ejecutivoDr. Malte Peters, M.D.
Número de empleados82
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 18
Dirección350 Fifth Avenue, 72Nd Floor, Suite 7240
CiudadNEW YORK
Bolsa de valoresUS 'Other OTC' and Grey Market
PaísUnited States of America
Código postal10118
Teléfono114318906360
Sitio Webhttps://www.hookipapharma.com/
Símbolo de cotizaciónHOOK
Fecha de salida a bolsaApr 18, 2019
Director ejecutivoDr. Malte Peters, M.D.
Ejecutivos de HOOKIPA Pharma Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Julie O'Neill
Ms. Julie O'Neill
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
496.00
-0.04%
Mr. Sean A. Cassidy
Mr. Sean A. Cassidy
Independent Director
Independent Director
--
--
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Dr. David R. Kaufman, M.D., Ph.D.
Dr. David R. Kaufman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Terry Coelho
Ms. Terry Coelho
Chief Financial Officer, Executive Vice President, Director
Chief Financial Officer, Executive Vice President, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Julie O'Neill
Ms. Julie O'Neill
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
496.00
-0.04%
Mr. Sean A. Cassidy
Mr. Sean A. Cassidy
Independent Director
Independent Director
--
--
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Dr. David R. Kaufman, M.D., Ph.D.
Dr. David R. Kaufman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Terry Coelho
Ms. Terry Coelho
Chief Financial Officer, Executive Vice President, Director
Chief Financial Officer, Executive Vice President, Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de HOOKIPA Pharma Inc?
Los cinco principales accionistas de HOOKIPA Pharma Inc son: Ms. Julie O'Neill
¿Cuántas instituciones poseen acciones de HOOKIPA Pharma Inc (HOOK)?
A fecha de 2026Q1, 73 instituciones poseen acciones de HOOKIPA Pharma Inc, con un valor de mercado combinado de aproximadamente 327.48K, lo que representa el 3.30% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3304608.00.